Lmfa07050031

Lmfa07050031 is a lipid of Fatty Acyls (FA) class. The involved functions are known as Pigment and Polymerization. The related lipids are Propionate.

Cross Reference

Introduction

To understand associated biological information of Lmfa07050031, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Lmfa07050031?

There are no associated biomedical information in the current reference collection.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Lmfa07050031

MeSH term MeSH ID Detail
Diabetes Mellitus D003920 90 associated lipids
Adenocarcinoma D000230 166 associated lipids
Reperfusion Injury D015427 65 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Ketosis D007662 13 associated lipids
Body Weight D001835 333 associated lipids
Heart Failure D006333 36 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Hypothyroidism D007037 32 associated lipids
Per page 10 20 50 | Total 27

PubChem Associated disorders and diseases

What pathways are associated with Lmfa07050031

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Lmfa07050031?

There are no associated biomedical information in the current reference collection.

What functions are associated with Lmfa07050031?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Lmfa07050031?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Lmfa07050031?

There are no associated biomedical information in the current reference collection.

What common seen animal models are associated with Lmfa07050031?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Lmfa07050031

Download all related citations
Per page 10 20 50 100 | Total 787
Authors Title Published Journal PubMed Link
Onay-Besikci A and Sambandam N Malonyl CoA control of fatty acid oxidation in the newborn heart in response to increased fatty acid supply. 2006 Can. J. Physiol. Pharmacol. pmid:17218986
Li JN et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. 2001 Cancer Res. pmid:11245456
Brusselmans K et al. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. 2005 Cancer Res. pmid:16061653
Pizer ES et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. 2000 Cancer Res. pmid:10667561
Maurer I and Zierz S Carnitine palmitoyltransferase in patients with cardiac ischemia due to atherosclerotic coronary artery disease and in patients with idiopathic dilated cardiomyopathy. 1997 May-Jun Cardiology pmid:9129847
Wakil SJ et al. The fatty acid synthetase-structure-function relationship and mechanism of palmitate synthesis. 1981 Jul-Sep Cardiovasc Res Cent Bull pmid:7340934
Kudej RK et al. Second window of preconditioning normalizes palmitate use for oxidation and improves function during low-flow ischaemia. 2011 Cardiovasc. Res. pmid:21835931
Folmes CD and Lopaschuk GD Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. 2007 Cardiovasc. Res. pmid:17126822
Ussher JR and Lopaschuk GD The malonyl CoA axis as a potential target for treating ischaemic heart disease. 2008 Cardiovasc. Res. pmid:18499682
Ussher JR et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. 2012 Cardiovasc. Res. pmid:22436846
Zhabyeyev P et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. 2013 Cardiovasc. Res. pmid:23257023
Hall JL et al. Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels. 1996 Cardiovasc. Res. pmid:8944819
Mercier R et al. Excess membrane synthesis drives a primitive mode of cell proliferation. 2013 Cell pmid:23452849
Unger RH The hyperleptinemia of obesity-regulator of caloric surpluses. 2004 Cell pmid:15084251
Giordano A et al. tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1. 2005 Cell Death Differ. pmid:15846373
Dean JT et al. Resistance to diet-induced obesity in mice with synthetic glyoxylate shunt. 2009 Cell Metab. pmid:19490907
Kelley DE Pulling in more fat. 2005 Cell Metab. pmid:16271525
Neschen S et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. 2005 Cell Metab. pmid:16054099
López M et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. 2008 Cell Metab. pmid:18460330
Zammit VA and Arduini A The AMPK-malonyl-CoA-CPT1 axis in the control of hypothalamic neuronal function. 2008 Cell Metab. pmid:18762014
Zhang S and Kim KH Essential role of acetyl-CoA carboxylase in the glucose-induced insulin secretion in a pancreatic beta-cell line. 1998 Cell. Signal. pmid:9502115
Awakawa T et al. Physically discrete beta-lactamase-type thioesterase catalyzes product release in atrochrysone synthesis by iterative type I polyketide synthase. 2009 Chem. Biol. pmid:19549600
Zhou P et al. Polyketide synthase acyl carrier protein (ACP) as a substrate and a catalyst for malonyl ACP biosynthesis. 1999 Chem. Biol. pmid:10421763
Jensen K et al. Polyketide proofreading by an acyltransferase-like enzyme. 2012 Chem. Biol. pmid:22444588
Kage H et al. An iterative type I polyketide synthase initiates the biosynthesis of the antimycoplasma agent micacocidin. 2013 Chem. Biol. pmid:23790487
Ellis JM and Wolfgang MJ A genetically encoded metabolite sensor for malonyl-CoA. 2012 Chem. Biol. pmid:23102226
Hitchman TS et al. Catalytic self-acylation of type II polyketide synthase acyl carrier proteins. 1998 Chem. Biol. pmid:9479478
Hamed RB et al. Carboxymethylproline synthase catalysed syntheses of functionalised N-heterocycles. 2010 Chem. Commun. (Camb.) pmid:20162132
Nicholson TP et al. First in vitro directed biosynthesis of new compounds by a minimal type II polyketide synthase: evidence for the mechanism of chain length determination. 2003 Chem. Commun. (Camb.) pmid:12703773
Tosin M et al. Malonyl carba(dethia)- and malonyl oxa(dethia)-coenzyme A as tools for trapping polyketide intermediates. 2009 Chembiochem pmid:19507202
Musiol EM et al. The ATâ‚‚ domain of KirCI loads malonyl extender units to the ACPs of the kirromycin PKS. 2013 Chembiochem pmid:23828654
Awakawa T et al. 4-Hydroxy-3-methyl-6-(1-methyl-2-oxoalkyl)pyran-2-one synthesis by a type III polyketide synthase from Rhodospirillum centenum. 2013 Chembiochem pmid:23609937
Foster DW and McGarry JD The regulation of ketogenesis. 1982 Ciba Found. Symp. pmid:6122545
Lewandowski ED et al. Acute liver carnitine palmitoyltransferase I overexpression recapitulates reduced palmitate oxidation of cardiac hypertrophy. 2013 Circ. Res. pmid:22982985
Kolwicz SC et al. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. 2012 Circ. Res. pmid:22730442
Dyck JR et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. 2004 Circ. Res. pmid:15105298
Zierz S et al. Biochemical evidence for heterozygosity in muscular carnitine palmitoyltransferase deficiency. 1993 Clin Investig pmid:8136624
Zierz S Limited trypsin proteolysis renders carnitine palmitoyltransferase insensitive to inhibition by malonyl-CoA in patients with muscle carnitine palmitoyltransferase deficiency. 1994 Clin Investig pmid:7711426
Escrivá F et al. Effect of feeding pattern on the sensitivity of hepatic carnitine palmitoyl-transferase to inhibition by malonyl-CoA in the rat. 1987 Comp Biochem Physiol A Comp Physiol pmid:2887369
Wen J and Kerr RG Purification and characterization of the fatty acid synthase from Bugula neritina. 2001 Comp. Biochem. Physiol. B, Biochem. Mol. Biol. pmid:11250539
Gutières S et al. Cloning and tissue distribution of a carnitine palmitoyltransferase I gene in rainbow trout (Oncorhynchus mykiss). 2003 Comp. Biochem. Physiol. B, Biochem. Mol. Biol. pmid:12781981
Lavarías S et al. Partial characterization of a malonyl-CoA-sensitive carnitine O-palmitoyltransferase I from Macrobrachium borellii (Crustacea: Palaemonidae). 2009 Comp. Biochem. Physiol. B, Biochem. Mol. Biol. pmid:19171199
Svoronos S and Kumar S Decarboxylation of malonyl-CoA by lactating bovine mammary fatty acid synthase. 1988 Comp. Biochem. Physiol., B pmid:3396325
Lynen F New experiments of biotin enzymes. 1979 CRC Crit. Rev. Biochem. pmid:41682
McGrath RP Unusual case of metabolic acidosis. 1989 Crit. Care Med. pmid:2909311
Harwood HJ Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome. 2004 Curr Opin Investig Drugs pmid:15083594
Anderson RC Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM? 1998 Curr. Pharm. Des. pmid:10197030
Schujman GE et al. FapR, a bacterial transcription factor involved in global regulation of membrane lipid biosynthesis. 2003 Dev. Cell pmid:12737802
Foster DW Banting lecture 1984. From glycogen to ketones--and back. 1984 Diabetes pmid:6094292
Bandyopadhyay GK et al. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. 2006 Diabetes pmid:16873691